Cytokinetics Incorporated
Cytokinetics Incorporated (CYTK.nq) on the NASDAQ Exchange
Company overview
Cytokinetics Incorporated is a publicly listed company from USA with shares traded on NASDAQ under the ticker CYTK.nq. This page provides a live view of market pricing and an interactive chart to follow short and long-term moves without manual refresh. The latest streaming quotes for CYTK.nq are bid 310.6 USD and ask 312.45 USD.
Use the chart to review recent momentum, identify key price areas, and track how Cytokinetics Incorporated is performing relative to your portfolio in 2025. If you are researching the instrument for trading or investing, add CYTK.nq to your watchlist in R StocksTrader and compare it with other US and European shares, indices, and metals.
Key facts
- Exchange: NASDAQ
- Company: Cytokinetics Incorporated
- Ticker: CYTK.nq
- Country: USA
- Bid: 310.6 USD
- Ask: 312.45 USD
- Quotes: real-time, auto-updated
Risk
Risk Warning: Past performance of CYTK.nq does not predict future returns.
FAQ
Open a trading account at RoboForex, decide on the number of assets to buy, and then place an order for Cytokinetics Incorporated (CYTK.nq) in R StocksTrader. Create and verify your profile, fund the account, search for CYTK.nq, and choose the instrument type available to you. Add CYTK.nq to your Watchlist to track moves and manage open positions throughout 2025.
CYTK.nq trades on NASDAQ and is issued by Cytokinetics Incorporated. This page provides a live chart and continuously updated price data for the 2025 year so that you can follow intraday swings and longer trends. Before starting trading and placing orders, review trading hours, typical spreads, and fees in the terminal to make sure conditions for CYTK.nq match your plan.
Quotes update automatically in real time. Current levels for CYTK.nq are bid 310.6 USD and ask 312.45 USD. The spread is the difference between ask and bid and affects your effective entry and exit. Track CYTK.nq in R StocksTrader and adjust your approach as market conditions change in 2025.